Sernova Biotherapeutics Income Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Jan '26 Jan 31, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	2020 - 2016
Selling, General & Admin	6.99	7.52	8.97	8.46	7.86	2.3	Upgrade
Research & Development	5.35	7.5	22.69	32.04	16.9	4.64	Upgrade
Operating Expenses	12.34	15.02	31.66	40.5	24.75	6.94	Upgrade
Operating Income	-12.34	-15.02	-31.66	-40.5	-24.75	-6.94	Upgrade
Interest Expense	-1	-0.75	-0.59	-0.03	-0.05	-0.01	Upgrade
Interest & Investment Income	0	0.03	0.39	1.5	0.58	0.07	Upgrade
Currency Exchange Gain (Loss)	0.83	-0.04	-0.34	0.04	-0.13	-0.04	Upgrade
Other Non Operating Income (Expenses)	-	-	-	-	-0.07	-0.05	Upgrade
EBT Excluding Unusual Items	-12.51	-15.79	-32.2	-39	-24.42	-6.97	Upgrade
Gain (Loss) on Sale of Assets	0.06	0.06	0.02	-	-	-	Upgrade
Pretax Income	-12.45	-15.73	-32.19	-39	-24.42	-6.97	Upgrade
Income Tax Expense	-0.07	0.01	0.01	-	-	-	Upgrade
Net Income	-12.38	-15.74	-32.19	-39	-24.42	-6.97	Upgrade
Net Income to Common	-12.38	-15.74	-32.19	-39	-24.42	-6.97	Upgrade
Shares Outstanding (Basic)	331	328	307	303	274	246	Upgrade
Shares Outstanding (Diluted)	331	328	307	303	274	246	Upgrade
Shares Change (YoY)	5.60%	6.95%	1.19%	10.87%	11.43%	24.45%	Upgrade
EPS (Basic)	-0.04	-0.05	-0.10	-0.13	-0.09	-0.03	Upgrade
EPS (Diluted)	-0.04	-0.05	-0.10	-0.13	-0.09	-0.03	Upgrade
Free Cash Flow	-7.13	-10.91	-18.9	-30.44	-14.75	-6.86	Upgrade
Free Cash Flow Per Share	-0.02	-0.03	-0.06	-0.10	-0.05	-0.03	Upgrade
EBITDA	-12.12	-14.77	-31.25	-40.19	-24.45	-6.69	Upgrade
D&A For EBITDA	0.21	0.26	0.41	0.31	0.3	0.24	Upgrade
EBIT	-12.34	-15.02	-31.66	-40.5	-24.75	-6.94	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.